News

Press Releases

Published: 18 December 2024

ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal Dystrophies

• VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to target the genetic root cause of retinal dystrophies associated with ABCA4 mutations • VG801 IND clearance expands ViGeneron’s clinical-stage pipeline to two programs, utilizing its novel gene therapy delivery technology platforms vgAAV capsid and […]

Published: 10 April 2024

ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 For the Intravitreal Treatment of Retinitis Pigmentosa

VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoceptor target cells in retinitis pigmentosa patients VG901, using ViGeneron’s proprietary next-generation technology platform vgAAV, is administered intravitreally (IVT), offering enhanced ease of delivery, broader vector distribution, and mitigating the risk of retinal damage linked with subretinal administration […]

Published: 25 October 2023

Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology

REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissues Potential to address prevalent inherited diseases caused by larger genes such as Stargardt disease Delivery of CRISPR modules allows bi-directional modulation of multiple genes   Munich, Germany, October 25, 2023 –– ViGeneron […]

Published: 22 August 2023

ViGeneron announces EMA Approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa

Munich, Germany, August 22, 2023 –– ViGeneron GmbH (ViGeneron), a next-generation gene therapy company, today announced that the European Medicines Agency (EMA) has approved the Clinical Trial Application (CTA) for VG901, a potentially transformative gene therapy to treat CNGA1-associated Retinitis Pigmentosa (RP), an ocular disorder currently lacking approved therapies. VG901 uses vgAAV, ViGeneron’s proprietary adeno-associated […]

Published: 30 June 2023

ViGeneron welcomes Dr. Markus Kalousek as Chief Business & Strategy Officer to drive next phase of corporate development

Munich, Germany, June 30, 2023 –– ViGeneron GmbH, a next-generation gene therapy company, announced the appointment of Dr. Markus Kalousek as Chief Business & Strategy Officer (CBO) effective July 1st, 2023, to advance the next stage of corporate development. With more than 25 years of experience in the international biopharmaceutical sector, mainly in large corporations, […]

Published: 12 May 2023

ViGeneron to present preclinical efficacy and safety data on intravitreal gene therapy of Retinitis Pigmentosa at ASGCT

First gene therapy program targeting CNGA1 mutation in Retinitis Pigmentosa (RP) Novel vgAAV vector efficiently and safely delivers human CNGA1 gene via intravitreal injection in RP disease model ViGeneron to advance its VG901 program for RP through clinical development Munich, Germany, May 12, 2023 –– ViGeneron GmbH, a next-generation gene therapy company, announced today that […]

Published: 11 October 2022

ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT

Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development Munich, Germany, October 11, 2022 –– ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of preclinical data on its program VG801 […]

Published: 26 April 2022

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases • The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases Munich, Germany, April 26, 2022 –– ViGeneron GmbH, a next-generation gene therapy […]

Published: 6 April 2022

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

• Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product • ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales • The collaboration […]

Published: 18 January 2021

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease

Published: 5 January 2021

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

ViGeneron has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.

Published: 1 December 2020

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership For Next-Generation Ophthalmic Gene Therapy

ViGeneron has announced a strategic partnership with WuXi Advanced Therapies Inc., a leading Contract, Testing, Development and Manufacturing Organization to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.

Published: 28 November 2019

ViGeneron Announces Closing of Series A Financing to Drive Development of Next Generation Gene Therapy Pipeline

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. Funds will advance development of ViGeneron’s […]

Events

There are no events scheduled at the moment

In The Media

Published: 13 May 2022

Bioworld: Vigeneron carves out space in evolving AAV gene therapy landscape

Although gene therapy is now “a clinical reality,” it still remains an early stage therapeutic modality. That’s the view of Caroline Man Xu, CEO and co-founder of Vigeneron GmbH, a German gene therapy company that has maintained a low profile while steadily staking out a promising position in gene therapies for inherited retinal disease.– Full […]

Published: 26 April 2022

PharmaTimes: ViGeneron and Daiichi Sankyo to develop therapy for eye diseases

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates ViGeneron and Daiichi Sankyo have agreed a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vGAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases. The two companies have been working on a programme together […]

Published: 6 April 2022

Endpoints News: Building on its retinal disease expertise, Regeneron signs eye-focused gene therapy pact with German biotech

Regeneron beefed up its gene therapy capabilities Wednesday, signing a new deal with the German biotech ViGeneron. The similarly named — but unrelated — companies announced the collaboration early Wednesday morning, one which would see ViGeneron receive undisclosed upfront and milestone payments in exchange for Regeneron getting access to its suite of recombinant adeno-associated virus […]

Published: 6 April 2022

Biopharma Dive:Regeneron, in search of an eye gene therapy, turns to a young biotech

Dive Brief: • Through a deal announced Wednesday, a German-based biotechnology company has agreed to help Regeneron develop a gene therapy for an inherited retinal disease. • The company, ViGeneron, claims to have an improved method for engineering the viral vehicles often used to shuttle genetic medicine into the proper cells. So far, ViGeneron’s research […]

Published: 6 April 2022

Fierce Biotech: Hunting for next big eye disease drug, Regeneron gets deeper into gene therapies with ViGeneron pact

Regeneron is dipping its toe deeper into the gene therapy waters, teaming up with ViGeneron to work on a retinal disease prospect based on engineered recombinant adeno-associated virus vectors (vgAAVs). While best known for its antibody work, Regeneron has a history of exploring other modalities through dealmaking, inking a $640 million gene therapy pact with Avalanche […]

Published: 5 January 2021

S&P Global: ViGeneron collaborates with Biogen to develop gene therapies for eye diseases

ViGeneron GmbH is collaborating with Biogen Inc. to develop gene therapies for the treatment of inherited eye diseases. The companies will use Germany-based ViGeneron’s proprietary vgAAV gene therapy vector technology to efficiently transduce retinal cells by injecting medicine into the eye. ViGeneron, a gene therapy developer, will focus on optimizing and validating therapies for an […]

Published: 5 January 2021

Endpoints News: Edging toward a pivotal readout, Biogen picks a new discovery partner for ophthalmic gene therapy

Almost two years after Biogen swooped again into the ophthalmic gene therapy field with an $800 million buyout of eye-focused Nightstar Therapeutics, it’s turning to a young player for a new program. Germany’s ViGeneron will be deploying its next-generation AAV vectors to generate candidates for a target — Biogen isn’t disclosing which exactly — that […]

Published: 2 December 2020

Genengnews: ViGeneron and WuXi Form Strategic Manufacturing Partnership

ViGeneron, a gene therapy company, and WuXi Advanced Therapies, a contract, testing, development, and manufacturing organization (CTDMO), entered into a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. ViGeneron’s lead product, VG901, targets a disease gene for Retinitis pigmentosa (RP), for which there is currently no […]

Published: 29 November 2019

Pharmaphorum: ViGeneron to develop next-gen eye gene therapies after funding round

Germany’s ViGeneron is to advance development of its next-generation ophthalmology gene therapy pipeline after a series A financing round. The privately-owned Munich-based biotech did not say how much it had raised from the financing round, which was led by WuXi AppTec and Sequoia Capital China. But ViGeneron said the proceeds will allow it to accelerate […]